Frank Glavin, CEO
Frank Glavin is CEO of Orphan Technologies, a Neopharm company focused on the research and development of innovative therapies. In addition, he is the Vice President of Neovii Biotech North America and a member of the Neovii Executive Management Committee. He oversees the group’s strategy, clinical and commercial development, and operations. Mr. Glavin joined the company in 2009 and brings 15+ years of drug and commercial development experience in both public and private companies to Neovii. Previously he was Director of Therapeutics at CombinatoRx where he spearheaded translational drug development advancing 2 products from the lab to the clinic. Prior to that, Mr. Glavin developed processes and frameworks to plan, execute, and measure the portfolio of strategic initiatives as a member of the Serono Strategic Planning team and was a Life Science Management Consultant developing new-business incubation, in-licensing and acquisition, and franchise development strategies for global pharmaceutical and health care clients. Mr. Glavin has a B.S. in Human Physiology from Boston University as well as an MBA from the Johnson Graduate School of Management at Cornell University.
Dr. Neil Kirby is a pharmaceutical executive with 30 years of experience with leading biotechnology companies including Biogen, Genetics Institute, Vertex, TKT and Stromedix. He is currently CEO of Phoenix Tissue Repair. Previously, he was President and CEO of Edimer Pharmaceuticals, a company dedicated to the development of an innovative treatment for the rare genetic condition XLHED (X-linked hypohidrotic ectodermal dysplasia). Dr. Kirby has held positions of increasing responsibility in global regulatory affairs, strategic planning, portfolio management, non-clinical development, manufacturing and program management. During his career, Dr. Kirby has been involved with the development, registration and successful commercial launches of several important therapeutic biopharmaceuticals (including coagulation factors, cytokines and enzyme replacement therapies). Dr. Kirby has received his Ph.D. in the faculty of medicine form the University of London in the UK.
Margaret (Margie) McGlynn is a biopharmaceutical executive with significant commercial leadership experience, who is now focused on developing new treatments and a patient support group for homocystinuria, a rare genetic disease that affected her family. After receiving a dual degree in Pharmacy and MBA in Marketing, Margie spent 26 years at Merck where she served in leadership roles in marketing, new product development and managed care, last serving as President, Global Vaccines and Anti-Infectives. After leaving Merck, Margie then served for 4 years as President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), a Product Development Partnership which helps accelerate HIV vaccine development by bridging government and philanthropic funding with academic and industry vaccine research and development capabilities.
Margie is also the founder and President of the Hempling Foundation for Homocystinuria Research, which she established in 2009 to support research for new therapies to address homocystinuria, a rare genetic disease that led to an early death of 2 of her sisters. She is also working to help establish a U.S. and global patient support group for patients with homocystinuria.
Margie also serves on the boards of Air Products and Chemicals, Vertex Pharmaceuticals and Amicus Therapeutics.
Deborah Ramsdell has 30 years of experience in the design and implementation of worldwide development strategies for therapeutic drugs and biotechnology products. Over the course of her career, she has been responsible for the strategic design and operational oversight of more than 70 drug candidates in the fields of oncology, rare metabolic diseases, dermatology, pain, infectious diseases, transplantation, cardiology, renal diseases, and endocrinology.
She is a Master’s level educator with degrees in Biology and Education and has been a senior level executive in the biotechnology industry as well as a strategic consultant to biotechnology and pharmaceutical companies for most of her career.
Andreas (Andy) Sidler is an expert in the investment management field. He spent 15 years at UBS, the largest Swiss bank, where he worked as a stock trader. After obtaining the federal diploma in financial analysis and portfolio management he changed from investment banking to the asset management department, where he managed the portfolios of large institutional clients.
In 2002, he joined Edrofin Asset Management AG, a small Zurich based asset management firm. In 2003, he became a CFA charter holder. He is a client relationship manager and member of the investment committee. Andy is also responsible for the Portfolio Management/CRM software and for the business administration. He became a Partner in 2012.
Andy is also member of the board of Neovii pharmaceuticals AG.
Neovii Pharmaceuticals AG CEO, Alexandre Sudarskis has extensive 37 years’ experience in the pharmaceutical industry. After obtaining his diplomas in Law and Economy at University Lyon III, he held Senior Executive positions at InstitutMerieux (Sanofi Pasteur / Merial) in charge of international commercial and marketing operations in animal healthcare and human biology.
After acquisition in 2006 of Chiron Corporation, he was appointed at the Novartis Vaccines and Diagnostic Division Executive Committee, which had sales of more than USD 1.3 billion. As a member of the Executive Committee, based in Basel, he was responsible for International Business Operation (USD 350 million). In his recent roles Alexandre Sudarskis was Managing Director Novartis Vaccines France, Member of Executive Committee Novartis Pharma France, Chair Administrator of Chiron Panacea Vaccines India and Novartis Behring India (Rabies vaccine manufacturer) and lately Head of International Alliances and Partnership at Viropharma.